Poor prognosis of KRAS or BRAF mutant colorectal liver metastasis without microsatellite instability

Journal of Hepato-Biliary-Pancreatic Sciences

Volumn 20, Issue 2, 2013, Pages 223-233

  Umeda, Yuzo ^a   Nagasaka, Takeshi ^a   Mori, Yoshiko ^a   Sadamori, Hiroshi ^a   Sun, Dong Sheng ^a   Shinoura, Susumu ^a   Yoshida, Ryuich ^a   Satoh, Daisuke ^a   Nobuoka, Daisuke ^a   Utsumi, Masashi ^a   Yoshida, Kazuhiro ^a   Yagi, Takahito ^a   Fujiwara, Toshiyoshi ^a  

^a OKAYAMA UNIVERSITY   (Japan)

Author keywords

BRAF; Colorectal cancer; KRAS; Liver metastasis; Microsatellite instability

Indexed keywords

B RAF KINASE; BEVACIZUMAB; CETUXIMAB; FLUOROURACIL; GENOMIC DNA; IRINOTECAN; OXALIPLATIN;

AGED; ARTICLE; BRAF GENE; CANCER PROGNOSIS; COLORECTAL LIVER METASTASIS; CONTROLLED STUDY; DISEASE FREE SURVIVAL; FEMALE; HUMAN; HUMAN TISSUE; LIVER RESECTION; MAJOR CLINICAL STUDY; MALE; MICROSATELLITE INSTABILITY; ONCOGENE K RAS; OVERALL SURVIVAL; SOMATIC MUTATION;

AGED; COLORECTAL NEOPLASMS; DISEASE PROGRESSION; DNA MUTATIONAL ANALYSIS; DNA, NEOPLASM; FEMALE; FOLLOW-UP STUDIES; HUMANS; JAPAN; LIVER NEOPLASMS; MALE; MICROSATELLITE INSTABILITY; MUTATION; POLYMERASE CHAIN REACTION; PROGNOSIS; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS B-RAF; RAS PROTEINS; RETROSPECTIVE STUDIES; SURVIVAL RATE; TUMOR MARKERS, BIOLOGICAL;

EID: 84879685038     PISSN: 18686974     EISSN: 18686982     Source Type: Journal    
DOI: 10.1007/s00534-012-0531-9     Document Type: Article

References (49)

1. Boyle P, Levin B. IARC: colorectal cancer. World Cancer report. Lyon: IARC; 2008. p. 374.
2. World Cancer Research Fund AlfCR. Food nutrition, physical activity and the prevention of cancer: a global perspective. Washington, DC: American institute for Cancer Research; 2007.
3. Adam R, Vinet E. Regional treatment of metastasis: surgery of colorectal liver metastases. Ann Oncol. 2004, 15 Suppl 4:iv103-6.
4. Jaffe BM, Donegan WL, Watson F, Spratt JS Jr. Factors influencing survival in patients with untreated hepatic metastases. Surg Gynecol Obstet. 1968;127(1):1-11.
5. Scheele J, Stangl R, Altendorf-Hofmann A. Hepatic metastases from colorectal carcinoma: impact of surgical resection on the natural history. Br J Surg. 1990;77(11):1241-6.
6. Masi G, Loupakis F, Pollina L, Vasile E, Cupini S, Ricci S, et al. Long-term outcome of initially unresectable metastatic colorectal cancer patients treated with 5-fluorouracil/leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) followed by radical surgery of metastases. Ann Surg. 2009;249(3):420-5.
7. Adam R, Aloia T, Levi F, Wicherts DA, de Haas RJ, Paule B, et al. Hepatic resection after rescue cetuximab treatment for colorectal liver metastases previously refractory to conventional systemic therapy. J Clin Oncol. 2007;25(29):4593-602.
8. Nordlinger B, Sorbye H, Glimelius B, Poston GJ, Schlag PM, Rougier P, et al. Perioperative chemotherapy with FOLFOX4 and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC Intergroup trial 40983): a randomised controlled trial. Lancet. 2008;371(9617):1007-16.
9. Kopetz S, Abbruzzese JL. Hidden biases in an observational study of bevacizumab beyond progression. J Clin Oncol. 2009;27(10):1732-3 (author reply 1733).
10. Geiersbach KB, Samowitz WS. Microsatellite instability and colorectal cancer. Arch Pathol Lab Med. 2011;135(10):1269-77.
11. Hampel H, Frankel WL, Martin E, Arnold M, Khanduja K, Kuebler P, et al. Screening for the Lynch syndrome (hereditary nonpolyposis colorectal cancer). N Engl J Med. 2005;352(18):1851-60.
12. Abdel-Rahman WM, Peltomaki P. Lynch syndrome and related familial colorectal cancers. Crit Rev Oncog. 2008;14(1):1-22 (discussion 23-31).
13. Muller A, Fishel R. Mismatch repair and the hereditary non-polyposis colorectal cancer syndrome (HNPCC). Cancer Invest. 2002;20(1):102-9.
14. Park JG, Kim DW, Hong CW, Nam BH, Shin YK, Hong SH, et al. Germ line mutations of mismatch repair genes in hereditary nonpolyposis colorectal cancer patients with small bowel cancer: International Society for Gastrointestinal Hereditary Tumours Collaborative Study. Clin Cancer Res. 2006;12(11 Pt 1):3389-93.
15. Goel A, Nagasaka T, Arnold CN, Inoue T, Hamilton C, Niedzwiecki D, et al. The CpG island methylator phenotype and chromosomal instability are inversely correlated in sporadic colorectal cancer. Gastroenterology. 2007;132(1):127-38.
16. Nagasaka T, Sasamoto H, Notohara K, Cullings HM, Takeda M, Kimura K, et al. Colorectal cancer with mutation in BRAF, KRAS, and wild-type with respect to both oncogenes showing different patterns of DNA methylation. J Clin Oncol. 2004;22(22):4584-94.
17. Lengauer C, Kinzler KW, Vogelstein B. Genetic instability in colorectal cancers. Nature. 1997;386(6625):623-7.
18. Nagasaka T, Koi M, Kloor M, Gebert J, Vilkin A, Nishida N, et al. Mutations in both KRAS and BRAF may contribute to the methylator phenotype in colon cancer. Gastroenterology. 2008;134(7):1950-1960, 1960 e1951.
19. Boland CR, Goel A. Microsatellite instability in colorectal cancer. Gastroenterology. 2010;138(6):2073-87 e2073.
20. Lievre A, Bachet JB, Le Corre D, Boige V, Landi B, Emile JF, et al. KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer. Cancer Res. 2006;66(8):3992-5.
21. Amado RG, Wolf M, Peeters M, Van Cutsem E, Siena S, Freeman DJ, et al. Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. J Clin Oncol. 2008;26(10):1626-34.
22. Peeters M, Price T, Hotko Y, Cervantes A, Ducreux M, Andre T, et al. Randomized phase 3 study of panitumumab (PMAB) with FOLFIRI compared to FOLFIRI alone as second-line treatment (TX) for metastatic colorectal cancer (MCRC): secondary endpoint results. Ann Oncol. 2010;21:15.
23. Peyssonnaux C, Eychene A. The Raf/MEK/ERK pathway: new concepts of activation. Biol Cell. 2001;93(1-2):53-62.
24. Davies H, Bignell GR, Cox C, Stephens P, Edkins S, Clegg S, et al. Mutations of the BRAF gene in human cancer. Nature. 2002;417(6892):949-54.
25. Rajagopalan H, Bardelli A, Lengauer C, Kinzler KW, Vogelstein B, Velculescu VE. Tumorigenesis: RAF/RAS oncogenes and mismatch-repair status. Nature. 2002;418(6901):934.
26. Roth AD, Tejpar S, Delorenzi M, Yan P, Fiocca R, Klingbiel D, et al. Prognostic role of KRAS and BRAF in stage II and III resected colon cancer: results of the translational study on the PETACC-3, EORTC 40993, SAKK 60-00 trial. J Clin Oncol. 2010;28(3):466-74.
27. Japanese classification of colorectal carcinoma. 2nd English edition. Tokyo: Kanehara; 2009.
28. Goel A, Nagasaka T, Hamelin R, Boland CR. An optimized pentaplex PCR for detecting DNA mismatch repair-deficient colorectal cancers. PLoS One. 2010;5(2):e9393.
29. Koopman M, Kortman GA, Mekenkamp L, Ligtenberg MJ, Hoogerbrugge N, Antonini NF, et al. Deficient mismatch repair system in patients with sporadic advanced colorectal cancer. Br J Cancer. 2009;100(2):266-73.
30. Parc Y, Gueroult S, Mourra N, Serfaty L, Flejou JF, Tiret E, et al. Prognostic significance of microsatellite instability determined by immunohistochemical staining of MSH2 and MLH1 in sporadic T3N0M0 colon cancer. Gut. 2004;53(3):371-5.
31. Ribic CM, Sargent DJ, Moore MJ, Thibodeau SN, French AJ, Goldberg RM, et al. Tumor microsatellite-instability status as a predictor of benefit from fluorouracil-based adjuvant chemotherapy for colon cancer. N Engl J Med. 2003;349(3):247-57.
32. French AJ, Sargent DJ, Burgart LJ, Foster NR, Kabat BF, Goldberg R, et al. Prognostic significance of defective mismatch repair and BRAF V600E in patients with colon cancer. Clin Cancer Res. 2008;14(11):3408-15.
33. Etienne-Grimaldi MC, Formento JL, Francoual M, Francois E, Formento P, Renee N, et al. K-Ras mutations and treatment outcome in colorectal cancer patients receiving exclusive fluoropyrimidine therapy. Clin Cancer Res. 2008;14(15):4830-5.
34. Heinemann V, Stintzing S, Kirchner T, Boeck S, Jung A. Clinical relevance of EGFR- and KRAS-status in colorectal cancer patients treated with monoclonal antibodies directed against the EGFR. Cancer Treat Rev. 2009;35(3):262-71.
35. Bleeker WA, Hayes VM, Karrenbeld A, Hofstra RM, Hermans J, Buys CC, et al. Impact of KRAS and TP53 mutations on survival in patients with left- and right-sided Dukes' C colon cancer. Am J Gastroenterol. 2000;95(10):2953-7.
36. Amado RG, Wolf M, Peeters M, Van Cutsem E, Siena S, Freeman DJ, et al. Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. J Clin Oncol. 2008;26(10):1626-34.
37. Esteller M, Gonzalez S, Risques RA, Marcuello E, Mangues R, Germa JR, et al. K-ras and p16 aberrations confer poor prognosis in human colorectal cancer. J Clin Oncol. 2001;19(2):299-304.
38. Tortola S, Marcuello E, Gonzalez I, Reyes G, Arribas R, Aiza G, et al. p53 and K-ras gene mutations correlate with tumor aggressiveness but are not of routine prognostic value in colorectal cancer. J Clin Oncol. 1999;17(5):1375-81.
39. Westra JL, Schaapveld M, Hollema H, de Boer JP, Kraak MM, de Jong D, et al. Determination of TP53 mutation is more relevant than microsatellite instability status for the prediction of disease-free survival in adjuvant-treated stage III colon cancer patients. J Clin Oncol. 2005;23(24):5635-43.
40. Richman SD, Seymour MT, Chambers P, Elliott F, Daly CL, Meade AM, et al. KRAS and BRAF mutations in advanced colorectal cancer are associated with poor prognosis but do not preclude benefit from oxaliplatin or irinotecan: results from the MRC FOCUS trial. J Clin Oncol. 2009;27(35):5931-7.
41. Andreyev HJ, Norman AR, Cunningham D, Oates J, Dix BR, Iacopetta BJ, et al. Kirsten ras mutations in patients with colorectal cancer: the 'RASCAL II' study. Br J Cancer. 2001;85(5):692-6.
42. Andreyev HJ, Norman AR, Cunningham D, Oates JR, Clarke PA. Kirsten ras mutations in patients with colorectal cancer: the multicenter "RASCAL" study. J Natl Cancer Inst. 1998;90(9):675-84.
43. Ogino S, Meyerhardt JA, Irahara N, Niedzwiecki D, Hollis D, Saltz LB, et al. KRAS mutation in stage III colon cancer and clinical outcome following intergroup trial CALGB 89803. Clin Cancer Res. 2009;15(23):7322-9.
44. Benatti P, Gafà R, Barana D, Marino M, Scarselli A, Pedroni M, et al. Microsatellite instability and colorectal cancer prognosis. Clin Cancer Res. 2005;11:8332-40.
45. Raut C, Pawlik T, Rodriguez-Bigas MA. Clinicopathologic features in colorectal cancer patients with microsatellite instability. Mutat Res. 2004;568:275-82.
46. Popat S, Hubner R, Houlston RS. Systematic review of microsatellite instability and colorectal cancer prognosis. J Clin Oncol. 2005;23:609-18.
47. Yuen ST, Davies H, Chan TL, Ho JW, Bignell GR, Cox C, et al. Similarity of the phenotypic patterns associated with BRAF and KRAS mutations in colorectal neoplasia. Cancer Res. 2002;62(22):6451-5.
48. Yokota T, Ura T, Shibata N, Takahari D, Shitara K, Nomura M, et al. BRAF mutation is a powerful prognostic factor in advanced and recurrent colorectal cancer. Br J Cancer. 2011;104(5):856-62.
49. Tol J, Nagtegaal ID, Punt CJ. BRAF mutation in metastatic colorectal cancer. N Engl J Med. 2009;361(1):98-9.